PHARMACEUTICAL REAL GROWTH OF 10.1% IN 1996 WAS DRIVEN BY MANAGED CARE, IMS AMERICA SAYS: MANAGED CARE PATIENTS ARE GETTING MORE UNITS, SHELTER FROM COST
The dominance of managed care in the payment for pharmaceuticals is largely responsible for an "unprecedented" 10.1% real growth rate in the pharmaceutical industry in 1996, IMS VP-Global Client Services Richard Fehring said April 14 at a New York City press briefing.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth